Any 0 3 0 3 O
medical 4 11 4 11 B-chronic_disease
or 12 14 12 14 O
psychological 15 28 15 28 B-chronic_disease
condition 29 38 29 38 I-chronic_disease
that 39 43 39 43 O
in 44 46 44 46 O
the 47 50 47 50 O
opinion 51 58 51 58 O
of 59 61 59 61 O
the 62 65 62 65 O
principal 66 75 66 75 O
investigator 76 88 76 88 O
would 89 94 89 94 O
interfere 95 104 95 104 O
with 105 109 105 109 O
safe 110 114 110 114 O
completion 115 125 115 125 O
of 126 128 126 128 O
the 129 132 129 132 O
trial 133 138 133 138 O

Concurrent 0 10 139 149 O
second 11 17 150 156 B-cancer
malignancy 18 28 157 167 I-cancer
or 29 31 168 170 O
history 32 39 171 178 O
of 40 42 179 181 O
HER2 43 47 182 186 B-cancer
negative 48 56 187 195 I-cancer
breast 57 63 196 202 I-cancer
cancer 64 70 203 209 I-cancer
within 71 77 210 216 O
five 78 82 217 221 B-upper_bound
years 83 88 222 227 I-upper_bound

Eastern 0 7 228 235 B-clinical_variable
Cooperative 8 19 236 247 I-clinical_variable
Oncology 20 28 248 256 I-clinical_variable
Group 29 34 257 262 I-clinical_variable
Performance 35 46 263 274 I-clinical_variable
Status 47 53 275 281 I-clinical_variable
of 54 56 282 284 O
0 57 58 285 286 B-lower_bound
or 59 61 287 289 O
1 62 63 290 291 B-upper_bound
( 64 65 292 293 O
An 65 67 293 295 O
attempt 68 75 296 303 O
to 76 78 304 306 O
quantify 79 87 307 315 O
cancer 88 94 316 322 B-cancer
patients 95 103 323 331 O
' 103 104 331 332 O
general 105 112 333 340 O
well 113 117 341 345 O
- 117 118 345 346 O
being 118 123 346 351 O
and 124 127 352 355 O
activities 128 138 356 366 O
of 139 141 367 369 O
daily 142 147 370 375 O
life 148 152 376 380 O

Immunization 0 12 381 393 B-treatment
with 13 17 394 398 I-treatment
a 18 19 399 400 I-treatment
live 20 24 401 405 I-treatment
/ 24 25 405 406 I-treatment
attenuated 25 35 406 416 I-treatment
vaccine 36 43 417 424 I-treatment
within 44 50 425 431 O
30 51 53 432 434 B-upper_bound
days 54 58 435 439 I-upper_bound
of 59 61 440 442 O
enrollment 62 72 443 453 O

Intolerance 0 11 454 465 O
to 12 14 466 468 O
previous 15 23 469 477 O
trastuzumab 24 35 478 489 B-treatment
or 36 38 490 492 O
pertuzumab 39 49 493 503 B-treatment
therapy 50 57 504 511 I-treatment

Major 0 5 512 517 B-treatment
surgery 6 13 518 525 I-treatment
within 14 20 526 532 O
8 21 22 533 534 B-upper_bound
weeks 23 28 535 540 I-upper_bound
or 29 31 541 543 O
planned 32 39 544 551 B-treatment
major 40 45 552 557 I-treatment
surgery 46 53 558 565 I-treatment
during 54 60 566 572 O
study 61 66 573 578 O
and 67 70 579 582 O
up 71 73 583 585 O
to 74 76 586 588 O
6 77 78 589 590 B-upper_bound
months 79 85 591 597 I-upper_bound
after 86 91 598 603 O
discontinuation 92 107 604 619 O
of 108 110 620 622 O
study 111 116 623 628 O
drug 117 121 629 633 O

Males 0 5 634 639 B-gender

Pregnancy 0 9 640 649 B-pregnancy

Previous 0 8 650 658 O
treatment 9 18 659 668 B-treatment
with 19 23 669 673 O
tocilizumab 24 35 674 685 B-treatment
or 36 38 686 688 O
other 39 44 689 694 O
cytokine 45 53 695 703 B-treatment
- 53 54 703 704 I-treatment
targeted 54 62 704 712 I-treatment
biologic 63 71 713 721 I-treatment
disease 72 79 722 729 I-treatment
modifying 80 89 730 739 I-treatment
antirheumatic 90 103 740 753 I-treatment
drugs 104 109 754 759 I-treatment
( 110 111 760 761 O
including 111 120 761 770 O
adalimumab 121 131 771 781 B-treatment
, 131 132 781 782 O
certolizumab 133 145 783 795 B-treatment
, 145 146 795 796 O
etanercept 147 157 797 807 B-treatment
, 157 158 807 808 O
golimumab 159 168 809 818 B-treatment
, 168 169 818 819 O
infliximab 170 180 820 830 B-treatment
, 180 181 830 831 O
anakinra 182 190 832 840 B-treatment
) 190 191 840 841 O
within 192 198 842 848 O
3 199 200 849 850 B-upper_bound
months 201 207 851 857 I-upper_bound
of 208 210 858 860 O
enrollment 211 221 861 871 O

Primary 0 7 872 879 B-chronic_disease
or 8 10 880 882 I-chronic_disease
secondary 11 20 883 892 I-chronic_disease
immunodeficiency 21 37 893 909 I-chronic_disease
( 38 39 910 911 O
history 39 46 911 918 O
of 47 49 919 921 O
or 50 52 922 924 O
currently 53 62 925 934 O
active 63 69 935 941 O
) 69 70 941 942 O
unless 71 77 943 949 O
related 78 85 950 957 O
to 86 88 958 960 O
primary 89 96 961 968 O
disease 97 104 969 976 O
under 105 110 977 982 O
investigation 111 124 983 996 O

Prior 0 5 997 1002 B-treatment
therapy 6 13 1003 1010 I-treatment
with 14 18 1011 1015 O
other 19 24 1016 1021 O
HER2 25 29 1022 1026 B-treatment
targeted 30 38 1027 1035 I-treatment
agents 39 45 1036 1042 I-treatment
( 46 47 1043 1044 O
TDM-1 47 52 1044 1049 B-treatment
, 52 53 1049 1050 O
pertuzumab 54 64 1051 1061 B-treatment
, 64 65 1061 1062 O
lapatinib 66 75 1063 1072 B-treatment
) 75 76 1072 1073 O

Subjects 0 8 1074 1082 O
with 9 13 1083 1087 O
treated 14 21 1088 1095 O
brain 22 27 1096 1101 B-cancer
metastases 28 38 1102 1112 I-cancer
are 39 42 1113 1116 O
eligible 43 51 1117 1125 O
provided 52 60 1126 1134 O
the 61 64 1135 1138 O
metastases 65 75 1139 1149 O
are 76 79 1150 1153 O
clinically 80 90 1154 1164 O
stable 91 97 1165 1171 O
and 98 101 1172 1175 O
greater 102 109 1176 1183 O
than 110 114 1184 1188 O
8 115 116 1189 1190 B-lower_bound
weeks 117 122 1191 1196 I-lower_bound
has 123 126 1197 1200 O
elapsed 127 134 1201 1208 O
from 135 139 1209 1213 O
time 140 144 1214 1218 O
of 145 147 1219 1221 O
treatment 148 157 1222 1231 B-treatment
and 158 161 1232 1235 O
date 162 166 1236 1240 O
of 167 169 1241 1243 O
initiation 170 180 1244 1254 O
of 181 183 1255 1257 O
study 184 189 1258 1263 O
drug 190 194 1264 1268 O

The 0 3 1269 1272 O
last 4 8 1273 1277 O
radiation 9 18 1278 1287 B-treatment
therapy 19 26 1288 1295 I-treatment
must 27 31 1296 1300 O
have 32 36 1301 1305 O
occurred 37 45 1306 1314 O
â‰¥3 46 48 1315 1317 O
weeks 49 54 1318 1323 I-lower_bound
prior 55 60 1324 1329 I-lower_bound
to 61 63 1330 1332 O
study 64 69 1333 1338 O
registration 70 82 1339 1351 O

The 0 3 1352 1355 O
score 4 9 1356 1361 O
ranges 10 16 1362 1368 O
from 17 21 1369 1373 O
0 22 23 1374 1375 B-lower_bound
to 24 26 1376 1378 O
5 27 28 1379 1380 B-upper_bound
where 29 34 1381 1386 O
0 35 36 1387 1388 O
is 37 39 1389 1391 O
asymptomatic 40 52 1392 1404 O
and 53 56 1405 1408 O
5 57 58 1409 1410 O
is 59 61 1411 1413 O
death 62 67 1414 1419 O

Women 0 5 1420 1425 B-gender

females 0 7 1426 1433 B-gender
of 8 10 1434 1436 O
reproductive 11 23 1437 1449 O
potential 24 33 1450 1459 O

men 0 3 1460 1463 B-gender

must 0 4 1464 1468 O
use 5 8 1469 1472 B-contraception_consent
two 9 12 1473 1476 I-contraception_consent
forms 13 18 1477 1482 I-contraception_consent
of 19 21 1483 1485 I-contraception_consent
effective 22 31 1486 1495 I-contraception_consent
contraception 32 45 1496 1509 I-contraception_consent
during 46 52 1510 1516 O
the 53 56 1517 1520 O
duration 57 65 1521 1529 O
of 66 68 1530 1532 O
the 69 72 1533 1536 O
trial 73 78 1537 1542 O
and 79 82 1543 1546 O
for 83 86 1547 1550 O
minimum 87 94 1551 1558 O
of 95 97 1559 1561 O
7 98 99 1562 1563 B-lower_bound
months 100 106 1564 1570 I-lower_bound
after 107 112 1571 1576 O
last 113 117 1577 1581 O
dose 118 122 1582 1586 O
of 123 125 1587 1589 O
tocilizumab 126 137 1590 1601 B-treatment
, 137 138 1601 1602 O
trastuzumab 139 150 1603 1614 B-treatment
, 150 151 1614 1615 O
or 152 154 1616 1618 O
pertuzumab 155 165 1619 1629 B-treatment

